These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30496913)

  • 41. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy.
    Rungkitwattanakul D; Chaijamorn W; Charoensareerat T; Charntrakarn P; Khamkampud O; Rattanaponpasert N; Srisawat N; Pattharachayakul S
    J Crit Care; 2021 Jun; 63():154-160. PubMed ID: 33012583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
    Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
    J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation.
    Soraluce A; Barrasa H; Asín-Prieto E; Sánchez-Izquierdo JÁ; Maynar J; Isla A; Rodríguez-Gascón A
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31936614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating linezolid dose regimens against methicillin-resistant Staphylococcus aureus based on renal function in populations with different body weight.
    Zuo M; Sun Y; Zhao X; Xu G; Wang N; Chen J; Zhu L; Yang W; Zhao M
    J Clin Pharm Ther; 2022 Dec; 47(12):2162-2169. PubMed ID: 36053892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
    Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study.
    Charoensareerat T; Chaijamorn W; Boonpeng A; Srisawat N; Pummangura C; Pattharachayakul S
    J Crit Care; 2019 Dec; 54():77-82. PubMed ID: 31394493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains.
    Zhao W; Kong L; Wu C; Wu X
    Eur J Clin Pharmacol; 2021 Jan; 77(1):79-86. PubMed ID: 32812063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Foissac F; Bouazza N; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0113522. PubMed ID: 36342152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
    Jang SM; Pai MP; Shaw AR; Mueller BA
    Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic Dosing in Continuous Renal Replacement Therapy.
    Shaw AR; Mueller BA
    Adv Chronic Kidney Dis; 2017 Jul; 24(4):219-227. PubMed ID: 28778361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.